IN2014DN02346A - - Google Patents
Info
- Publication number
- IN2014DN02346A IN2014DN02346A IN2346DEN2014A IN2014DN02346A IN 2014DN02346 A IN2014DN02346 A IN 2014DN02346A IN 2346DEN2014 A IN2346DEN2014 A IN 2346DEN2014A IN 2014DN02346 A IN2014DN02346 A IN 2014DN02346A
- Authority
- IN
- India
- Prior art keywords
- dosage forms
- oral dosage
- compositions
- enylamino
- chloro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
- C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
- C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
- C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/48—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups having nitrogen atoms of sulfonamide groups further bound to another hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/04—Systems containing only non-condensed rings with a four-membered ring
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161530516P | 2011-09-02 | 2011-09-02 | |
| PCT/IB2012/054502 WO2013030803A1 (en) | 2011-09-02 | 2012-08-31 | Choline salt of an anti - inflammatory substituted cyclobutenedione compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2014DN02346A true IN2014DN02346A (ru) | 2015-05-15 |
Family
ID=47116123
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN2346DEN2014 IN2014DN02346A (ru) | 2011-09-02 | 2012-08-31 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US9018261B2 (ru) |
| EP (2) | EP2760821B1 (ru) |
| JP (3) | JP2014529621A (ru) |
| KR (1) | KR102024955B1 (ru) |
| CN (1) | CN103842330B (ru) |
| BR (1) | BR112014004963A2 (ru) |
| CA (1) | CA2846510C (ru) |
| EA (1) | EA201490552A1 (ru) |
| ES (1) | ES2655942T3 (ru) |
| HU (1) | HUE035751T2 (ru) |
| IN (1) | IN2014DN02346A (ru) |
| MX (1) | MX359259B (ru) |
| NO (1) | NO2679622T3 (ru) |
| PL (1) | PL2760821T3 (ru) |
| PT (1) | PT2760821T (ru) |
| SI (1) | SI2760821T1 (ru) |
| WO (1) | WO2013030803A1 (ru) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA103198C2 (en) | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| EP2764866A1 (en) | 2013-02-07 | 2014-08-13 | IP Gesellschaft für Management mbH | Inhibitors of nedd8-activating enzyme |
| TWI734715B (zh) | 2015-11-19 | 2021-08-01 | 美商卡默森屈有限公司 | 趨化因子受體調節劑 |
| TWI724056B (zh) | 2015-11-19 | 2021-04-11 | 美商卡默森屈有限公司 | Ｃｘｃｒ２抑制劑 |
| AU2018368731A1 (en) | 2017-11-16 | 2020-05-14 | Novartis Ag | Combination therapies |
| MA50424A (fr) | 2018-01-08 | 2020-08-26 | Chemocentryx Inc | Méthodes de traitement du psoriasis pustuleux généralisé avec un antagoniste de ccr6 ou cxcr2 |
| AR116109A1 (es) | 2018-07-10 | 2021-03-31 | Novartis Ag | Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos |
| AU2019402189B2 (en) | 2018-12-20 | 2023-04-13 | Novartis Ag | Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives |
| BR112021015672A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona substituída e usos dos mesmos |
| BR112021015783A2 (pt) | 2019-02-15 | 2021-10-05 | Novartis Ag | Derivados de 3-(1-oxo-5-(piperidin-4-il)isoindolin-2-il)piperidina-2,6-diona e usos dos mesmos |
| KR20220116257A (ko) | 2019-12-20 | 2022-08-22 | 노파르티스 아게 | 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물 |
| CN115916199A (zh) | 2020-06-23 | 2023-04-04 | 诺华股份有限公司 | 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案 |
| JP2023536164A (ja) | 2020-08-03 | 2023-08-23 | ノバルティス アーゲー | ヘテロアリール置換３－（１－オキソイソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用 |
| TW202304979A (zh) | 2021-04-07 | 2023-02-01 | 瑞士商諾華公司 | 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途 |
| AR125874A1 (es) | 2021-05-18 | 2023-08-23 | Novartis Ag | Terapias de combinación |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506252A (en) | 1993-11-17 | 1996-04-09 | American Home Products Corporation | Substituted N-heteroaryl and N-aryl-1,2-diaminocyclobutene-3,4-diones |
| AU686896B2 (en) | 1994-11-16 | 1998-02-12 | American Home Products Corporation | Diaminocyclobutene-3,4-diones |
| US5840764A (en) | 1997-01-30 | 1998-11-24 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| AU6250298A (en) | 1997-01-30 | 1998-08-25 | American Home Products Corporation | Substituted hydroxy-anilino derivatives of cyclobutene-3,4-diones |
| US6166050A (en) | 1998-12-14 | 2000-12-26 | American Home Products Corporation | 3,4-diamino-3-cyclobutene-1,2-dione derivatives which inhibit leukocyte adhesion mediated by VLA-4 |
| FR2815345B1 (fr) | 2000-10-12 | 2002-12-13 | Servier Lab | Nouveaux derives de cyclobutene-dione, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0028844D0 (en) | 2000-11-27 | 2001-01-10 | Celltech Chiroscience Ltd | Chemical compounds |
| WO2002067919A1 (en) | 2001-01-16 | 2002-09-06 | Smithkline Beecham Corporation | Il-8 receptor antagonists |
| ATE346043T1 (de) | 2001-01-16 | 2006-12-15 | Smithkline Beecham Corp | Il-8-rezeptorantagonisten |
| US20030175349A1 (en) * | 2001-01-30 | 2003-09-18 | Council Of Scientific And Industrial Research | Pharmaceutical compostion for extended/sustained release of a therapeutically active ingredient |
| WO2002062761A1 (en) | 2001-02-07 | 2002-08-15 | Abbott Laboratories | Aminal diones as potassium channel openers |
| EP1383488A2 (en) | 2001-03-30 | 2004-01-28 | SmithKline Beecham Corporation | Methods of synthesizing phenol-containing compounds |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| MXPA03009441A (es) | 2001-04-16 | 2004-02-12 | Schering Corp | Ciclobuteno-1,2-dionas 3,4-disustituidas como ligandos del receptor de quimocina cxc. |
| US7132445B2 (en) | 2001-04-16 | 2006-11-07 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| US20040097547A1 (en) | 2001-04-16 | 2004-05-20 | Taveras Arthur G. | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| WO2003000245A1 (en) | 2001-06-22 | 2003-01-03 | Poseidon Pharmaceuticals A/S | Compounds for use in disorders associated with mast cell or basophil activity |
| US20040053953A1 (en) | 2002-03-18 | 2004-03-18 | Schering Corporation | Treatment of chemokine mediated diseases |
| JP2009513512A (ja) * | 2003-07-09 | 2009-04-02 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | メロキシカムを含む組成物 |
| NZ548499A (en) | 2004-01-30 | 2010-06-25 | Schering Corp | Crystalline polymorphs of a CXC-chemokine receptor ligand |
| JP2007522217A (ja) * | 2004-02-10 | 2007-08-09 | サンタラス インコーポレイティッド | プロトンポンプ阻害剤、緩衝剤および非ステロイド系抗炎症薬の組み合わせ |
| US7635694B2 (en) | 2004-02-27 | 2009-12-22 | Schering Corporation | Cyclobutenedione-containing compounds as inhibitors of hepatitis C virus NS3 serine protease |
| GB0407908D0 (en) * | 2004-04-07 | 2004-05-12 | Univ York | Ionic liquids |
| DE102004046492A1 (de) | 2004-09-23 | 2006-03-30 | Sanofi-Aventis Deutschland Gmbh | Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament |
| ATE432921T1 (de) | 2004-12-23 | 2009-06-15 | Gpc Biotech Ag | Quadratsäurederivate mit antiproliferativer wirkung |
| DE102005001053A1 (de) | 2005-01-07 | 2006-07-20 | Merck Patent Gmbh | Quadratsäurederivate |
| WO2006084661A1 (de) | 2005-02-10 | 2006-08-17 | Wacker Chemie Ag | Lacke enthaltend partikel mit geschützten isocyanatgruppen |
| WO2006088920A1 (en) | 2005-02-16 | 2006-08-24 | Schering Corporation | Amine-linked pyridyl and phenyl substituted piperazine-piperidines with cxcr3 antagonist activity |
| DE102005035742A1 (de) | 2005-07-29 | 2007-02-01 | Merck Patent Gmbh | Quadratsäurederivate II |
| DE102005035741A1 (de) | 2005-07-29 | 2007-02-08 | Merck Patent Gmbh | Quadratsäurederivate |
| WO2008005570A1 (en) | 2006-07-07 | 2008-01-10 | Schering Corporation | 3,4-di-substituted cyclobutene-1,2-diones as cxc-chemokine receptor ligands |
| US8450348B2 (en) | 2007-02-21 | 2013-05-28 | Forma Tm, Llc | Derivatives of squaric acid with anti-proliferative activity |
| JP2010520292A (ja) | 2007-03-07 | 2010-06-10 | アラントス・フアーマシユーテイカルズ・ホールデイング・インコーポレイテツド | 複素環式部分を含有するメタロプロテアーゼ阻害剤 |
| JP2010529079A (ja) | 2007-06-06 | 2010-08-26 | ノバルティス アーゲー | 抗炎症性置換シクロブテンジオン化合物 |
| WO2009005801A1 (en) | 2007-07-03 | 2009-01-08 | Schering Corporation | Process and intermediates for the synthesis of 1,2-substituted 3,4-dioxo-1-cyclobutene compounds |
| JP2010532357A (ja) | 2007-07-05 | 2010-10-07 | シェーリング コーポレイション | １，２−置換３，４−ジオキソ−１−シクロブテン化合物における制御された結晶サイズのための方法 |
| WO2009012375A2 (en) | 2007-07-19 | 2009-01-22 | Wyeth | Squarate kinase inhibitors |
| WO2009073683A2 (en) | 2007-12-04 | 2009-06-11 | Schering Corporation | Methods of treating copd |
| PT2444120T (pt) | 2007-12-10 | 2018-01-03 | Novartis Ag | Análogos da amilorida espirocíclicos como bloqueadores de enac |
| WO2010002418A2 (en) * | 2008-07-01 | 2010-01-07 | The Johns Hopkins University | Quick-dissolving oral thin film for targeted delivery of therapeutic agents |
| TWI454476B (zh) | 2008-07-08 | 2014-10-01 | Tibotec Pharm Ltd | 用作ｃ型肝炎病毒抑制劑之巨環吲哚衍生物 |
| MX2011001127A (es) | 2008-08-04 | 2011-03-21 | Merck Patent Gmbh | Compuestos novedosos de fenilamino-isonicotinamida. |
| UA103198C2 (en) * | 2008-08-04 | 2013-09-25 | Новартис Аг | Squaramide derivatives as cxcr2 antagonists |
| AU2009313867A1 (en) * | 2008-11-14 | 2011-06-30 | Patheon Inc. | Solid composition for controlled release of ionizable active agents with poor aqueous solubility at low pH and methods of use thereof |
| WO2010063802A1 (en) | 2008-12-05 | 2010-06-10 | Novartis Ag | 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists |
| WO2010091543A1 (en) | 2009-02-10 | 2010-08-19 | Merck Sharp & Dohme Corp. | Novel hydrazino-cyclobut-3-ene-1, 2-dione derivatives as cxcr2 antagonists |
-
2012
- 2012-08-31 CN CN201280047528.3A patent/CN103842330B/zh not_active Expired - Fee Related
- 2012-08-31 HU HUE12780535A patent/HUE035751T2/hu unknown
- 2012-08-31 WO PCT/IB2012/054502 patent/WO2013030803A1/en active Application Filing
- 2012-08-31 EP EP12780535.6A patent/EP2760821B1/en not_active Not-in-force
- 2012-08-31 PT PT127805356T patent/PT2760821T/pt unknown
- 2012-08-31 IN IN2346DEN2014 patent/IN2014DN02346A/en unknown
- 2012-08-31 KR KR1020147008317A patent/KR102024955B1/ko active IP Right Grant
- 2012-08-31 ES ES12780535.6T patent/ES2655942T3/es active Active
- 2012-08-31 BR BR112014004963A patent/BR112014004963A2/pt active Search and Examination
- 2012-08-31 EA EA201490552A patent/EA201490552A1/ru unknown
- 2012-08-31 EP EP17191365.0A patent/EP3287438A1/en not_active Withdrawn
- 2012-08-31 SI SI201231173T patent/SI2760821T1/en unknown
- 2012-08-31 CA CA2846510A patent/CA2846510C/en not_active Expired - Fee Related
- 2012-08-31 JP JP2014527801A patent/JP2014529621A/ja active Pending
- 2012-08-31 PL PL12780535T patent/PL2760821T3/pl unknown
- 2012-08-31 MX MX2014002492A patent/MX359259B/es active IP Right Grant
- 2012-08-31 US US14/241,306 patent/US9018261B2/en not_active Expired - Fee Related
-
2013
- 2013-06-26 NO NO13173884A patent/NO2679622T3/no unknown
-
2016
- 2016-09-08 JP JP2016175348A patent/JP6612200B2/ja not_active Expired - Fee Related
-
2018
- 2018-07-19 JP JP2018135448A patent/JP2019001787A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20140206768A1 (en) | 2014-07-24 |
| JP6612200B2 (ja) | 2019-11-27 |
| US9018261B2 (en) | 2015-04-28 |
| NO2679622T3 (ru) | 2018-01-20 |
| HUE035751T2 (hu) | 2018-08-28 |
| JP2014529621A (ja) | 2014-11-13 |
| EA201490552A1 (ru) | 2014-11-28 |
| MX359259B (es) | 2018-09-20 |
| KR20140059264A (ko) | 2014-05-15 |
| JP2017025081A (ja) | 2017-02-02 |
| EP2760821A1 (en) | 2014-08-06 |
| BR112014004963A2 (pt) | 2017-03-21 |
| CA2846510C (en) | 2019-10-22 |
| PT2760821T (pt) | 2018-01-11 |
| ES2655942T3 (es) | 2018-02-22 |
| CA2846510A1 (en) | 2013-03-07 |
| EP2760821B1 (en) | 2017-10-11 |
| WO2013030803A1 (en) | 2013-03-07 |
| SI2760821T1 (en) | 2018-02-28 |
| CN103842330A (zh) | 2014-06-04 |
| JP2019001787A (ja) | 2019-01-10 |
| PL2760821T3 (pl) | 2018-04-30 |
| KR102024955B1 (ko) | 2019-09-24 |
| CN103842330B (zh) | 2016-10-19 |
| EP3287438A1 (en) | 2018-02-28 |
| MX2014002492A (es) | 2014-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IN2014DN02346A (ru) | ||
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| MX349159B (es) | Derivados deuterados de ivacaftor. | |
| EA201490228A1 (ru) | Новые производные трифторметилоксадиазола и их применение для лечения заболевания | |
| GT201400016A (es) | Indazoles | |
| UA111770C2 (uk) | Інгібітори бромдомену | |
| CA2818187C (en) | Bromodomain inhibitors and uses thereof | |
| WO2012116290A3 (en) | Neuroactive 17(20)-z-vinylcyano-substituted steroids, prodrugs thereof, and methods of treatment using same | |
| UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
| AU2012258977A8 (en) | Inhibitors of LRRK2 kinase activity | |
| MX2012006730A (es) | Tiazolidinadionas moderadoras de receptores activados por proliferador de peroxizoma (ppar) y combinaciones para tratamiento de enfermedades neurodegenerativas y otras enfermedades metabolicas. | |
| WO2011127333A3 (en) | Compounds for treating disease, for administering, and for pharmaceutical compositions | |
| CR20140134A (es) | Composiciones farmacéuticas | |
| IL224544B (en) | Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound | |
| PH12014502218A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| TR201901114T4 (tr) | Özgün immünomodülatör ve anti inflamatuvar bileşikler. | |
| BR112013019256A2 (pt) | inibição de il-17 e ifn-gama para o tratamento de inflamação autoimune | |
| WO2013170012A3 (en) | Proliposomal testosterone formulations | |
| RS53617B1 (en) | NEW UNITS USEFUL FOR TREATMENT OF DEGENERATIVE AND INFLAMMATORY DISEASES | |
| BR112013029730A2 (pt) | composição farmacêutica de rosuvastatina cálcica | |
| EA201590726A1 (ru) | Лахинимод для уменьшения таламического поражения при рассеянном склерозе | |
| MX2012001134A (es) | Composiciones y metodos para inhibicion de la via jak. | |
| EP3060220A4 (en) | Compositions for oral administration of zoledronic acid or related compounds for treating disease | |
| UY33530A (es) | Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias | |
| MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. |